Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Expert Discusses Phase III Trial of Frontline Pembrolizumab in MSI-H Colorectal Cancer

June 30th 2017

Luis A. Diaz, MD, discusses KEYNOTE-177 and the implications of the FDA approval of pembrolizumab for patients with MSI-H or dMMR CRC or other solid tumors.

Expert Discusses Tumor Location and Mutational Status in CRC

June 30th 2017

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.

HA Levels Predict PEGPH20 Response in Metastatic Pancreatic Cancer

June 29th 2017

The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

June 29th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

June 29th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic Cancer

June 29th 2017

Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.

Emerging Approaches in Liver Cancer

June 28th 2017

Frontline Lenvatinib vs Sorafenib in HCC

June 28th 2017

Second-Line Systemic Therapy in HCC

June 28th 2017

HCC: Managing Patients on Frontline Systemic Therapy

June 28th 2017

Transitioning to Systemic Therapy in HCC

June 28th 2017

Frontline SIRT vs Systemic Therapy in HCC

June 28th 2017

Initial Approaches in Locally Advanced HCC

June 28th 2017

Ablation vs Resection in Liver Cancer

June 28th 2017

Risk/Benefit of Expanding Liver Transplant Criteria

June 28th 2017

Impact of Liver Cirrhosis in HCC

June 28th 2017

Understanding BCLC Criteria in Liver Cancer Staging

June 28th 2017

Diagnosing HCC: When a Biopsy is Needed

June 28th 2017

Screening for HCC: Current and Emerging Biomarkers

June 28th 2017

Global Trends in HCC Risk Factors

June 28th 2017